Given that across all cancers, somatic ERBB3 mutations occur at a frequency of 2.1%, these findings support a rationale for treating cancers with these alterations with kinase inhibitors and/or therapeutic antibodies targeting ErbB2/ErbB3. Here, ERBB3 is linked to cancer.